Colorectal Cancer and Immunity: From the Wet Lab to Individuals

Pramil, Élodie; Dillard, Clémentine; Escargueil, Alexandre E.

doi:10.3390/cancers13071713

Cited by 4 publications

(2 citation statements)

References 170 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cancer cells may undergo transitions to enhance their motility and extravasate to colonize at distant locations 1 , 18 . Prior studies have demonstrated the existence of phenotypically different subpopulations of tumorigenic and non-tumorigenic cells in various human malignancies, including acute myeloid leukaemia 19 , 20 , chronic myeloid leukaemia 21 , 22 , breast cancer 23 , 24 , glioblastoma 25 , 26 , colorectal cancer 27 , 28 , pancreatic cancer 29 , 30 , and ovarian cancers 23 , 31 . Recent investigations revealed the presence of multiple heterogenic cancer cells, such as Epithelial to mesenchymal transition (EMTs) 32 , 33 , Mesenchymal to epithelial transitions (METs) 18 , 34 , Circulating tumor cells (CTCs) 24 , 35 , Disseminated Tumor Cells (DTCs) 36 , 37 , etc., in many cancer progression and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Quantum dots based in-vitro co-culture cancer model for identification of rare cancer cell heterogeneity

Vyshnava

Pandluru

Kumar

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Cancer cell heterogeneity (CCH) is crucial in understanding cancer progression and metastasis. The CCH is one of the stumbling blocks in modern medicine's therapeutics and diagnostics . An in-vitro model of co-culture systems of MCF-7, HeLa, HEK-293, with THP-1 cells showed the occurrence of EpCAM positive (EpCAM+) and EpCAM negative (EpCAM−) heterogenetic cancer cell types labeled with the Quantum Dot antibody conjugates (QDAb). This in-vitro model study could provide insights into the role of rare cancer cells manifestation and their heterogeneity in metastatic progression and risk for severe infections in these patients. We successfully report the presence of CCH based on the fluorescence ratios of the co-cultured cancer cells when treated with the QDAb. These short-term mimic co-cultures give a compelling and quite associated model for assessing early treatment responses in various cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantum dots based in-vitro co-culture cancer model for identification of rare cancer cell heterogeneity

Vyshnava

Pandluru

Kumar

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Intratumor heterogeneity and inter-tumor heterogeneity, among other molecular, phenotypic, and functional characteristics, can obstruct diagnosis and pose therapeutic challenges in bone, lung, brain, and liver cancer metastasis, these reports suggest that there is currently no systematic and comprehensive assessment of the molecular makeup of metastases 7 . Few reports have demonstrated the existence of phenotypically different subpopulations of tumorigenic and non-tumorigenic cells in various human malignancies, including acute myeloid leukaemia 8,9 , chronic myeloid leukaemia 10,11 , breast cancer 12,13 , glioblastoma 14,15 , colorectal cancer 16,17 , pancreatic cancer 18,19 , and ovarian cancers 12,20 .…”

Section: Introductionmentioning

confidence: 99%

Quantum Dots Based in-Vitro Co-Culture Cancer Model for Identification of Rare Cancer Cell Heterogeneity

Pandluru

et al. 2021

Preprint

View full text Add to dashboard Cite

Cancer cell heterogeneity (CCH) is a key element in understanding cancer progression and metastasis. CCH is one of the challenges in therapeutics and diagnostics stumbling block in modern medicine. An in-vitro model of co-culture systems of MCF-7, HeLa, HEK-293, with THP-1 cells showed the occurrence of CTCs like cells with EpCAM+ and other cancer cell heterogenetic types with the Quantum Dot antibody conjugates (QDAb). This in-vitro model study could provide insights into the role of rare cancer cells and heterogeneity in metastasis, as well as the severity of infections in these patients. We successfully reported the presence of CCH based on the fluorescence ratios of the co-culture cancer cells. These short-term mimic co-cultures give a compelling and quite associated model for estimating early treatment responses in various types of cancers.

show abstract

Irreversible Electroporation has More Synergistic Effect with Anti‐PD‐1 Immunotherapy than Thermal Ablation or Cryoablation, in a Colorectal Cancer Model

Jiang,

Shao,

Slaughter

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Boosting the response rate of immune checkpoint blockade (ICB) therapy to improve treatment efficacy is a primary goal in cancer immunotherapy. One of the promising approaches involves focal tumor ablation to reduce tumor burden and trigger the in situ vaccination. Even though this combination strategy has demonstrated enhanced therapeutic outcomes in both preclinical research and clinical trials, limited research has comparatively investigated diverse ablation techniques. The optimal choice among focal therapy techniques remains largely unknown. In a murine colorectal cancer model (MC‐38), the therapeutic efficacy of anti‐PD‐1 in combination with thermal ablation, cryoablation, and irreversible electroporation (IRE) is evaluated, utilizing well‐characterized miniature probes. In this model, ICB monotherapy has limited effect in controlling tumor growth. IRE exhibits the most favorable synergistic effect with anti‐PD‐1 immunotherapy than thermal ablation or cryoablation, leading to the greatest primary tumor growth delay, longest tumor‐free survival, and highest protection against secondary tumor challenge. Furthermore, the co‐administration of IRE and anti‐PD‐1 significantly fosters the infiltration of CD8+ T cells into the tumor coupled with a remarkable stem‐like progenitor phenotype. The findings demonstrate that IRE stands as a promising modality that can potentiate the antitumor efficacy when the tumor is poorly responding to ICB monotherapy.

show abstract

Colorectal Cancer and Immunity: From the Wet Lab to Individuals

Cited by 4 publications

References 170 publications

Quantum dots based in-vitro co-culture cancer model for identification of rare cancer cell heterogeneity

Quantum dots based in-vitro co-culture cancer model for identification of rare cancer cell heterogeneity

Quantum Dots Based in-Vitro Co-Culture Cancer Model for Identification of Rare Cancer Cell Heterogeneity

Irreversible Electroporation has More Synergistic Effect with Anti‐PD‐1 Immunotherapy than Thermal Ablation or Cryoablation, in a Colorectal Cancer Model

Contact Info

Product

Resources

About